🟢 PFE.BA is trading 2.6% up today as shares rebound from a pullback following its IBRANCE FDA rally

PFE.BA is trading 2.6% up at $9370 as shares rebound from a two-day slide following a rally driven by positive regulatory news.

• The stock's recent volatility stems from the U.S. FDA’s expanded approval of Pfizer’s IBRANCE regimen for HR+ metastatic breast cancer.
• IBRANCE is now the first CDK4/6 inhibitor approved across HER2 status, a milestone that initially sparked strong gains before profit-taking set in.